MET-097 is a glucagon-like peptide 1 receptor (GLP-1R) agonist developed at Metsera for treating overweight and obesity and is currently in phase II clinical trials.

The IPO market for med-tech companies continues to set new records. With one IPO closed the last week of June, two slated for ...

Inmune Bio Inc. claimed a phase II win with TNF inhibitor Xpro (pegipanermin) in early Alzheimer’s disease (AD), though the ...

Monoclonal antibodies show strong therapeutic potential against neurodegenerative diseases, but a major challenge is ensuring ...

Actinium Pharmaceuticals Inc. recently presented data on ATNM-400, a new antibody radioconjugate that uses actinium-225 ...

Vitsgen Therapeutics Inc. recently provided details on the preclinical characterization of a new prostate-specific membrane ...

The top 10 biopharma stock gainers and losers for the week.

Solid phase III efficacy results for Moderna Inc.’s seasonal influenza vaccine, mRNA-1010, may lead the company to resubmit a ...

Shemyakin Institute of Bioorganic Chemistry has synthesized perylenylethynylphenol derivatives acting as photosensitizers for photodynamic therapy reported to be useful for the treatment of SARS-CoV-2 ...

Many cancers involve upregulation of Aurora kinase B, which helps deregulate normal cell cycling to drive tumor proliferation. The kinase should therefore be a good therapeutic target, yet no ...

The efficacy of camptothecin-based topoisomerase I (Topo1) inhibitors, which are widely used as anticancer therapies, is often limited by resistance mechanisms, primarily involving mutations in the ...

The top 10 med-tech stock gainers and losers for the week.